Ovarian Cancer Immunotherapy and Personalized Medicine.

Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. · 2021

Read Ovarian Cancer Immunotherapy and Personalized Medicine. by Morand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc8234871.txt.

Description

Morand and co-authors assess ovarian cancer immunotherapy through the lens of personalised medicine. Response to immunotherapy in this cancer stays limited so far. Sorting patients by tumour markers may sharpen who benefits.

Markers under study include tumour mutation burden and PD-L1 levels. Infiltrating lymphocytes and DNA repair faults also count. Neoantigen diversity inside the tumour adds another signal. The review covers new drugs and trial designs built on these markers. Matching treatment to tumour traits is the path forward, they argue. Biomarker-led trials should raise success rates. Patient sorting is the thread that runs through every section.

Catalog record

CREATORMorand S, Devanaboyina M, Staats H, Stanbery L, Nemunaitis J.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE83 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC8234871

Browse the full library · About the Tower of Babel